news tirzepatide Zepbound copycats remain online despite FDA ban Lilly, Novo Fight Weight Loss
Description
The injection belongs to the class of GLP-1 receptor agonist drugs sold locally by Novo Nordisk, Eli Lilly, and Innovent Biologics
doi: 10.1037/hea0001517
Tirzepatide is a dual GIP and GLP-1 receptor agonist with no known direct effect on renal potassium handling or aldosterone activity
March 19, 2025 for 503B) Published Clinical Data: SURMOUNT-1 trial published in New England Journal of Medicine (Jastreboff et al., 2022) Independent Surveys: Gallup Health and Well-Being Index (October 2025)
When your inner world isnt at its best, it reflects in every aspect of your life
Pay month-to-month cancel anytime
